{
  "model": "gemini-3-pro-preview",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "result": {
    "text": "Study overview JSON: output/study_overview.json\nQuantitative findings JSON: output/quantitative_findings.json\nClaim audit JSON: output/claim_audit.json\nPublic summary JSON: output/public_summary.json",
    "thoughts": "**Checking File Outputs**\n\nI've completed writing the four output files, as confirmed by the tool. I'm taking a final pass to ensure I didn't overlook any details. The tool's success messages provide a good degree of confidence, but a quick spot check is always wise.\n\n\n**Confirming Final Details**\n\nThe file writes went well. I reviewed the outputs, and I'm confident. I won't re-read the files; the write confirmations are sufficient. Now, on to the checklist.",
    "steps": [
      {
        "step": 1,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Beginning the Process**\n\nI've just started by identifying the primary actions: read and execute. My immediate focus is on the `TASK.md` file. I'm initiating the reading phase, which is the essential first step.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md"
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools."
          }
        ],
        "usage": {
          "promptTokens": 240,
          "responseTokens": 13,
          "thinkingTokens": 30,
          "totalTokens": 283
        },
        "costUsd": 0.000996
      },
      {
        "step": 2,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Planning the Workflow**\n\n\\n\\n\n\nI've established the initial steps. I'll read the report and schemas first. Next, I'll generate the data, then output it into the specified JSON files. I'm focusing on the order and dependencies of these tasks now.\n\n\n**Identifying Schema Locations**\n\n\\n\\n\n\nMy primary focus is on locating and listing the schema files. The next step involves reading them to understand the data structure. Once the schemas are known, I can start generating data, and then move onto outputting the JSON files. I'm building this process step-by-step.",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas"
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json"
          }
        ],
        "usage": {
          "promptTokens": 736,
          "responseTokens": 11,
          "thinkingTokens": 124,
          "totalTokens": 871
        },
        "costUsd": 0.003092
      },
      {
        "step": 3,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Reviewing the Data Now**\n\nI've begun the process of meticulously going through the report and the associated schemas. My initial scan has revealed some interesting structural elements, and I'm starting to build a mental map of the data's organization. I'm focusing on the relationships between different data points.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md"
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified."
          }
        ],
        "usage": {
          "promptTokens": 778,
          "responseTokens": 15,
          "thinkingTokens": 11,
          "totalTokens": 804
        },
        "costUsd": 0.0018679999999999999
      },
      {
        "step": 4,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Beginning Schema Analysis**\n\nI've started to delve into the schema files. My initial focus is to grasp the fundamental structural requirements. I'm noting the key data points and how they relate to each other, to establish a framework for the work ahead.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json"
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }"
          }
        ],
        "usage": {
          "promptTokens": 1945,
          "responseTokens": 19,
          "thinkingTokens": 13,
          "totalTokens": 1977
        },
        "costUsd": 0.004274
      },
      {
        "step": 5,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Analyzing Quantitative Findings**\n\nI've initiated the review of the `quantitative_findings.schema.json` file. My immediate goal is to understand the structure of the quantitative data, focusing on the defined properties and data types. I'm paying close attention to any relationships or constraints that might exist within the schema to ensure proper interpretation.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json"
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }"
          }
        ],
        "usage": {
          "promptTokens": 3084,
          "responseTokens": 19,
          "thinkingTokens": 12,
          "totalTokens": 3115
        },
        "costUsd": 0.00654
      },
      {
        "step": 6,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Reviewing the Schema**\n\nI'm now carefully examining the `claim_audit.schema.json` file. My initial scan focused on key structural elements, but I'm now delving into the specific data types and constraints defined within. I'm looking for any potential data validation weaknesses or opportunities for optimization.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json"
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }"
          }
        ],
        "usage": {
          "promptTokens": 3992,
          "responseTokens": 19,
          "thinkingTokens": 12,
          "totalTokens": 4023
        },
        "costUsd": 0.008356
      },
      {
        "step": 7,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Examining Schema Details**\n\nI'm now diving into the `public_summary.schema.json` file. My goal is to extract the structure and understand the relationships between the different elements defined within this schema. Initial observations indicate a focus on data organization, and I will be sure to make note of all key fields.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json"
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }"
          }
        ],
        "usage": {
          "promptTokens": 4744,
          "cachedTokens": 3343,
          "responseTokens": 19,
          "thinkingTokens": 12,
          "totalTokens": 4775
        },
        "costUsd": 0.0038426
      },
      {
        "step": 8,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Analyzing Data Structures**\n\nI've reviewed the report and all schemas. I'm focusing on drafting data for each output file, starting with `output/study_overview.json`. I'm meticulously adhering to its schema at `schemas/study_overview.schema.json`. I plan to break this down into smaller, testable components.\n\n\n**Defining Schema Adherence**\n\nI'm deep in the process of mapping the report's details to the schema for `output/study_overview.json`. I've successfully populated the `paper` section, extracting the title, DOI, publication year, domain, and study type, as well as the `core_question`. The cohorts, mouse-efficacy and mouse-control are completed as well. Next, I need to resolve the human cohort.\n\n\n**Implementing Data Population**\n\nNow I am creating the structure for `output/study_overview.json`. I have successfully addressed the `paper`, `core_question`, and `datasets_or_cohorts` fields based on the input report.  I'm now integrating the `major_limitations` section, and thinking how to best represent them within the schema. This involves careful parsing of the limitations from the report to maintain semantic accuracy.\n\n\n**Constructing the Study Overview**\n\nI'm now populating the `output/study_overview.json` file. I've successfully extracted and formatted data for `paper`, `core_question`, and `datasets_or_cohorts`. I have a clear understanding of the input data and schema, and I'm ready to move on to structuring the `major_limitations` section, working through each point provided.\n\n\n**Constructing the Outputs**\n\nI am now beginning to populate the `output/study_overview.json` file. Following the schema, I am extracting data from the report to populate `paper`, `core_question`, and `datasets_or_cohorts`, which are complete. Next, I will be working on the `major_limitations` section, and thinking how to best represent them within the schema, including each point provided.\n\n\n**Generating Initial Data**\n\nI'm now starting to draft the data for `output/study_overview.json`, meticulously following its schema. I've populated the `paper` and `core_question` sections. I've also parsed and structured the `datasets_or_cohorts` field. I am ready to begin work on the `major_limitations` section, and thinking how to best represent them within the schema.\n\n\n**Creating the Output Files**\n\nI am now focusing on creating the output files. I've read the report and all the schemas. I will start with drafting the data for each output file, starting with the `output/study_overview.json` using the schema defined in `schemas/study_overview.schema.json`. I have begun to populate the `paper`, `core_question` and `datasets_or_cohorts` fields.\n\n\n**Constructing Outputs From Report**\n\nI'm now in the process of populating the data for the various output files, referencing the provided report details and corresponding schemas. I've begun populating `output/study_overview.json` and am meticulously extracting information for `paper`, `core_question`, and `datasets_or_cohorts`. I will proceed to populate the `major_limitations` section, and thinking how to best represent them within the schema.\n\n\n**Generating Output Data**\n\nI have read and understood the report, including the schemas. I'm now drafting the data, beginning with `output/study_overview.json`. I've populated the `paper`, `core_question`, and `datasets_or_cohorts` fields successfully. I'm now working to translate and structure the `major_limitations` section, ensuring each point is correctly represented in the output, and I am on track with all 4 schema.\n\n\n**Generating All Outputs**\n\nI'm now diving into the core task: creating the JSON output files. Following the plan, I've outlined the structure for `output/study_overview.json`, and started integrating the `major_limitations` section, and thinking how to best represent them within the schema. Next up: building `output/quantitative_findings.json`, `output/claim_audit.json`, and `output/public_summary.json` based on the report.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments receiving combination therapy.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls (vaccine only, ICI only, and vehicle).\"\n    },\n    {\n      \"id\": \"human-retro\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment.\"\n    },\n    {\n      \"id\": \"human-vac\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subgroup of patients who received prior SARS-CoV-2 mRNA vaccination.\"\n    },\n    {\n      \"id\": \"human-unvac\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subgroup of patients who had not received SARS-CoV-2 mRNA vaccination.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json"
          }
        ],
        "usage": {
          "promptTokens": 5590,
          "cachedTokens": 3417,
          "responseTokens": 579,
          "thinkingTokens": 2466,
          "totalTokens": 8635
        },
        "costUsd": 0.041569400000000006
      },
      {
        "step": 9,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Planning the Output File**\n\nI'm currently focused on the final output. My primary objective is to generate the `output/quantitative_findings.json` file. It seems straightforward, but I need to make sure I structure the data correctly for optimal use.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json"
          }
        ],
        "usage": {
          "promptTokens": 6180,
          "responseTokens": 777,
          "thinkingTokens": 12,
          "totalTokens": 6969
        },
        "costUsd": 0.021828
      },
      {
        "step": 10,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Defining the Output File**\n\nI'm currently focused on the specific output file. My primary decision is to write `output/claim_audit.json`. I need to solidify the structure of this JSON file, considering the data I plan to include.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination improves tumor sensitivity to anti-PD-L1 therapy.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The mechanism involves induction of Type I interferon signaling and improved antigen presentation.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Retrospective human data suggests prior mRNA vaccination correlates with better ICI outcomes.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Combined intervention ... aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Lipid nanoparticles alone are insufficient to cause the sensitization; mRNA is required.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n          \"line_ref\": \"L38\"\n        },\n        {\n          \"quote\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n          \"line_ref\": \"L36\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json"
          }
        ],
        "usage": {
          "promptTokens": 6968,
          "cachedTokens": 2686,
          "responseTokens": 635,
          "thinkingTokens": 12,
          "totalTokens": 7615
        },
        "costUsd": 0.0168652
      },
      {
        "step": 11,
        "modelVersion": "gemini-3-pro-preview",
        "thoughts": "**Generating a summary file**\n\nI'm focused on the task of creating `output/public_summary.json`. My current thought is to define the structure and content that should go into the file, ensuring it aligns perfectly with the user's needs. I'm prioritizing clarity and brevity in the output.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"COVID-19 mRNA Vaccines May Make Tumors More Vulnerable to Immunotherapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors are powerful cancer drugs that unleash the immune system to fight tumors, but they don't work for everyone. A new study published in Nature suggests that the technology used in COVID-19 mRNA vaccines might help overcome this limitation. Researchers found that injecting mRNA vaccines directly into tumors in mice triggered a strong inflammatory response, specifically a 'Type I interferon' signal. This signal acted like a flare, making the cancer cells more visible to the immune system by increasing the variety of proteins shown on their surface. When combined with standard immunotherapy (anti-PD-L1), the vaccine treatment significantly improved tumor control compared to immunotherapy alone. The study also looked back at records of 130 human patients with metastatic cancer treated with immunotherapy. Those who had previously received a SARS-CoV-2 mRNA vaccine showed better survival rates than those who hadn't. While these results are promising, the human data is preliminary and comes from looking at past records rather than a controlled trial. The findings point to a potential new way to prime 'cold' tumors to respond to treatment, but more research is needed to prove it works safely and effectively in patients.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA vaccination induces Type I interferon to prime tumors for immunotherapy.\",\n    \"The treatment expands the range of tumor antigens presented to the immune system.\",\n    \"Retrospective data links prior mRNA vaccination to better immunotherapy outcomes in humans.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human study was retrospective and non-randomized, meaning other factors could explain the results.\",\n    \"Animal model results do not always perfectly predict how the treatment will work in humans.\",\n    \"The timing of vaccination and the types of tumors treated varied significantly among patients.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune Checkpoint Inhibitor (ICI)\",\n      \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by blocking proteins that stop immune responses.\"\n    },\n    {\n      \"term\": \"Intratumoral\",\n      \"definition\": \"Administration of a drug or vaccine directly into a tumor mass.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of protein fragments (peptides) presented on the surface of cells that the immune system scans to detect infection or cancer.\"\n    },\n    {\n      \"term\": \"Type I Interferon\",\n      \"definition\": \"A group of signaling proteins released by cells in response to viruses that heighten the immune system's antiviral defenses.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein on cells that prevents the immune system from attacking them; blocking it is a common strategy in cancer immunotherapy.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will these results hold up in a prospective, randomized clinical trial?\",\n    \"What is the optimal timing for administering the mRNA vaccine relative to immunotherapy?\",\n    \"Can this approach work for all tumor types, or only specific ones?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json"
          }
        ],
        "usage": {
          "promptTokens": 7614,
          "cachedTokens": 5512,
          "responseTokens": 723,
          "thinkingTokens": 12,
          "totalTokens": 8349
        },
        "costUsd": 0.014126399999999999
      },
      {
        "step": 12,
        "modelVersion": "gemini-3-pro-preview",
        "text": "Study overview JSON: output/study_overview.json\nQuantitative findings JSON: output/quantitative_findings.json\nClaim audit JSON: output/claim_audit.json\nPublic summary JSON: output/public_summary.json",
        "thoughts": "**Checking File Outputs**\n\nI've completed writing the four output files, as confirmed by the tool. I'm taking a final pass to ensure I didn't overlook any details. The tool's success messages provide a good degree of confidence, but a quick spot check is always wise.\n\n\n**Confirming Final Details**\n\nThe file writes went well. I reviewed the outputs, and I'm confident. I won't re-read the files; the write confirmations are sufficient. Now, on to the checklist.",
        "toolCalls": [],
        "usage": {
          "promptTokens": 8348,
          "cachedTokens": 5653,
          "responseTokens": 47,
          "thinkingTokens": 134,
          "totalTokens": 8529
        },
        "costUsd": 0.0086926
      }
    ],
    "totalCostUsd": 0.1320502
  }
}
